Introduction {#s1}
============

Urothelial carcinoma (UC) originating from the bladder or upper urinary tracts (renal pelvis or ureter) is the most common histologic type of cancer. It generally shows chemo-sensitive feature. On the basis of these chemo-sensitivity of UC, platinum (cisplatin or carboplatin) based combination chemotherapy has long been used as first-line standard treatment for metastatic UC (mUC) ([@B1], [@B2]). With cisplatin-based regimens, 40--60% overall response rate (ORR) and median overall survival (OS) of 14--15 months can be expected for mUC patients ([@B3]--[@B5]). For mUC patients who are unfit for cisplatin-based regimens because of multiple comorbidities (i.e., neuropathy, hearing loss), poor performance status, or impaired renal function, carboplatin-based regimens are primarily applied as a feasible option, showing an 30--40% ORR and median OS of 9--10 months that are inferior results than those of cisplatin-based regimens ([@B6], [@B7]).

In spite of these efficacies of first-line treatments for mUC patients, a considerable number of patients experience disease progression during or after fist-line treatments. Therefore, they will require second-line therapy. Although several chemotherapeutic agents have been investigated in the second-line setting of mUC, they have only presented marginal activity with ORR of \<20% and median OS of \<9 months with considerable toxicity profiles ([@B8], [@B9]). Furthermore, there has been no evidence that second-line chemotherapy may improve OS or quality of life ([@B10]). Consequently, currently there are no approved second-line chemotherapeutic agents for mUC in the United States. According to current NCCN guidelines, paclitaxel and/or gemcitabine is the recommended second-line chemotherapeutic agents in post-platinum mUC due to higher ORR (\~40%) observed in a previous phase III study ([@B11], [@B12]). Vinflunine, a novel vinca alkaloid, is the only approved chemotherapeutic agent in the European Union based on results of phase III trials performed in the second-line setting of mUC ([@B13]--[@B15]).

In the last decades, with an increasing understanding of molecular biology and cancer immunobiology, research on systemic therapy in the oncologic field has mainly focused on targeted and immunotherapeutic agents other than cytotoxic chemotherapy ([@B9]). Lapatinib, a dual tyrosine kinase inhibitor (TKI) that targets human epidermal growth factor receptor (HER) pathway, has been evaluated as a possible second-line therapy in mUC ([@B16]). Besides, several immunotherapeutic agents that can block immune checkpoints, such as programmed cell death 1 (PD-1) or PD-ligand-1 (PD-L1), have been investigated in the second-line setting of mUC ([@B17]). Among these, atezolizumab (PD-L1 inhibitor) and pembrolizumab (PD-1 inhibitor) were approved by US-Food and Drug Administration (US-FDA) as the first or second line treatment in mUC based on durable therapeutic response and tolerable safety profiles observed in previous clinical trials ([@B18], [@B19]). However, consensus has not been reached yet regarding which second-line agent is the optimal treatment in terms of survival benefit in mUC.

Thus, the objective of the present study was to assess and compare the efficacy of each second-line treatment on OS improvement for determining the optimal therapeutic agent in post-platinum mUC setting. To achieve this goal, we conducted a network meta-analysis (NMA) of available data by only including phase III, randomized clinical trials (RCTs).

Materials and Methods {#s2}
=====================

The present NMA was performed and reported in line with recommendations of the preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement ([@B20]).

Search Strategy
---------------

We conducted an electronic search for clinical trials on second-line systemic therapeutic agents in mUC prior to December 2018 using PubMed, Embase, and the Cochrane Library. The search was limited to English articles with full-text publications. Search terms were used separately or in combination as followings: *(metastatic bladder cancer OR metastatic urothelial carcinoma OR metastatic bladder carcinoma) AND (systemic chemotherapy OR systemic treatment OR immune checkpoint inhibitor)*. Citation lists of all searched articles were then used to confirm other possible relevant publications. Only studies with well-established study design with comparative arms and explicit description of patients\' characteristics were finally selected. Two independent reviewers (HSK and CK) selected these articles. Any disagreements among reviewers were settled by consensus with a third reviewer (HHK).

Eligible Criteria
-----------------

Study eligibility was defined according to Population, Intervention, Comparator, Outcome, and Study design (PICOS) system ([@B20]): *Population*, Patients with mUC; *Interventions*, Second-line treatment after first-line chemotherapy; *Comparators*, Another second-line treatment (i.e., placebo, best supportive care); *Outcome*, OS; *Study design*, prospective RCTs with phase III design.

Articles were eligible if they met following inclusion criteria: (1) human research; (2) patients with mUC previously treated with the first-line systemic chemotherapy; (3) received second-line systemic treatment; (4) reported outcome value (OS); (5) available assessment for the association between second-line treatment and OS; (6) sufficient information provided to estimate hazard ratio (HR) and their 95% confidence interval (CI); and (7) RCTs. Exclusion criteria were as followings: review articles, letters, editorial comments, case reports, and articles that did not provide raw data.

Data Extraction
---------------

Three independent reviewers (HSY, HSK, and JHK) extracted the required information from all eligible studies and then compared their results to confirm accuracy. Any disagreements for extracted data between two reviewers were settled by consensus. Extracted data were recorded in accordance with reporting recommendations for tumor marker prognostic studies (REMARK) guidelines ([@B21]) as follows: (1) publication data including the name of the first author, year of publication, country, and recruitment period; (2) study characteristics including the number of patients, median age, and gender distribution in treatment and control groups, study endpoints, and duration of median follow-up; and (3) treatment characteristics including regimens, dosage of regimens, number of planned cycles, median OS, HR for OS with 95% CI, and percentage of grade 3 to grade 4 toxicity.

Statistical Analysis
--------------------

To indirectly compare the effect of each second-line therapeutic agent on OS, we performed NMA using a Bayesian model and Markov chain Monte Carlo methods called Gibbs sampling conducted in WinBUGS 1.4 (MRC Biostatistics Unit, Cambridge, UK) ([@B22]). Either a fixed or random effects model for reported outcomes was selected according to model fit criteria (Deviance Information Criteria, DIC) for penalizing greater model complexity ([@B23]). We modeled binary variables for every treatment group of every study. Results of NMA on OS were specified as HRs with 95% credible intervals (CrIs) across studies. Each analysis was based on non-informative priors for effect size and precision. We also suggested surface under the cumulative ranking (SUCRA) that represented ranking probabilities to provide a hierarchy of treatments accounting for both the location and the variance of all relative treatment effects ([@B24]), with higher value indicating better treatment ranking. Publication bias was explored using the funnel plot, the Egger\'s and the Begg\'s test. A symmetrical inverted funnel indicates no significant publication bias. Whereas, in the presence of publication bias, inverted funnel shows skewed and asymmetrical pattern. Besides, publication bias is significantly suspected if the *p*-values for the Begg\'s and Egger\'s tests are \<0.05 ([@B25], [@B26]). The Bayesian framework NMA was implemented with NetMetaXL which provided an interface using WinBUGS within Microsoft Excel ([@B27]). All *p*-values were two-sided and *p* \< 0.05 was considered statistically significant.

Results {#s3}
=======

Literature Search Results
-------------------------

We identified 232 articles after initial database searches. Among these, 80 duplicated publications were excluded. After reviewing titles and abstracts, 107 articles were also excluded. Thus, a total of 45 articles remained for full text review. According to inclusion criteria of our analysis, a total of 7 RCTs were finally selected for the current NMA ([@B12]--[@B16], [@B18], [@B19]). The PRISMA flow diagram depicting the process for literature search and selection of studies is presented in [Figure 1](#F1){ref-type="fig"}.

![PRISMA flow diagram describing the search strategy used for network meta-analysis.](fonc-09-00679-g0001){#F1}

Overview of Included Studies
----------------------------

### Study Characteristics

Characteristics of each included study are summarized in [Table 1](#T1){ref-type="table"}. All studies were phase III prospective RCTs published between 2009 and 2018. The recruitment period of patients ranged from 2001 to 2016. Randomization of patients to the treatment group and control group was made at ratio of 1:1 ([@B12], [@B16], [@B18], [@B19]) or 2:1 ([@B13]--[@B15]). Most studies considered OS as primary endpoint except for one study ([@B16]). Among these 7 studies, three studies ([@B13]--[@B15]) consisted of the same mUC cohort using specific agent (vinflunine) as second-line treatment. One was an original study ([@B13]). Another study presented long-term survival results with extended follow-up duration for the original study ([@B14]). The remaining study reported results of subgroup analysis conducted for mUC patients treated with prior cisplatin ([@B15]). Further characteristics of these eligible studies can be identified in [Table 1](#T1){ref-type="table"}.

###### 

Study characteristics of the eligible phase III randomized controlled trials for network meta-analysis.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Study**                                             **Year**   **Country**      **Recruitment period**   **Total patients (ITT)**   **Median age, years (range)**       **No. of gender (male/female)**   **Endpoints (primary/secondary)**   **Median follow-up duration (months)**
  ----------------------------------------------------- ---------- ---------------- ------------------------ -------------------------- ----------------------------------- --------------------------------- ----------------------------------- ----------------------------------------
  Albers et al. ([@B12])                                2011       Germany          2001--2005               Treatment arm: 48\         Treatment arm: 63.9 (42.8--80.6)\   NA                                OS/PFS, ORR, toxicity               NA
                                                                                                             Control arm: 48            Control arm: 65.1 (42.8--79.4)                                                                            

  Bellmunt et al. ([@B13]) (NCT00315237)                2009       Europe and USA   2003--2006               Treatment arm: 253\        64.3 (34.9--86.3)                   NA                                OS/ORR, PFS, DCR                    Treatment arm: 21.5\
                                                                                                             Control arm: 117                                                                                                                     Control arm: 22.3

  Bellmunt et al. ([@B14])                              2013       Europe and USA   2003--2006               Treatment arm: 253\        64.3 (34.9--86.3)                   NA                                OS/NA                               Treatment arm: 42\
                                                                                                             Control arm: 117                                                                                                                     Control arm: 45

  Harshman et al. ([@B15])                              2013       Europe and USA   2003--2006               Treatment arm: 167\        62.5 (34.6--82.3)                   NA                                OS/NA                               Treatment arm: 21.5\
                                                                                                             Control arm: 84                                                                                                                      Control arm: 22.3

  Powles et al. ([@B16]) (NCT00949455)                  2017       United Kingdom   2007--2013               Treatment arm: 116\        Treatment arm: 70.7 (63.9--77.2)\   Treatment arm: 88/28\             PFS/OS, ORR, toxicity               NA
                                                                                                             Control arm: 116           Control arm: 71.1 (63.8--76.3)      Control arm: 84/32                                                    

  Bellmunt et al. ([@B18]) (NCT02256436, KEYNOTE-045)   2017       Multi-nation     2014--2015               Treatment arm: 270\        Treatment arm: 67 (29--88)\         Treatment arm: 200/70\            OS, PFS/ORR, DOR, toxicity          14.1
                                                                                                             Control arm: 272           Control arm: 65 (26--84)            Control arm: 202/70                                                   

  Powles et al. ([@B19]) (NCT02302807, IMvigor211)      2018       Multi-nation     2015--2016               Treatment arm: 467\        Treatment arm: 67 (33--88)\         Treatment arm: 357/110\           OS/PFS, ORR, DOR, toxicity          17.3
                                                                                                             Control arm: 464           Control arm: 67 (31--84)            Control arm: 361/103                                                  
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*OS, overall survival; ORR, overall response rate; PFS, progression-free survival; DCR, disease control rate; NA, non-available, DOR; duration of response*.

Treatment Characteristics
-------------------------

Details on treatment characteristics of these eligible 7 studies are shown in [Table 2](#T2){ref-type="table"}. Second-line agents evaluated in treatment arms were as followings: vinflunine ([@B13]--[@B15]), gemcitabine/paclitaxel (GP) ([@B12]), lapatinib ([@B16]), pembrolizumab ([@B18]), and atezolizumab ([@B19]). The number of cycles was not clearly mentioned in most of these studies. Generally, the median OS ranged from 6.9 to 12.6 months in treatment arms and from 4.3 to 12.0 months in control arms. Among these assessed second-line agents, only two drugs (vinflunine, pembrolizumab) showed significant OS benefit relative to each control group (best supportive care, chemotherapeutic agents) ([@B13], [@B18]). The use of prolonged GP was significantly associated with higher treatment-related toxicity compared to short-term GP ([@B12]). In contrast, immune checkpoint inhibitors (ICIs) including pembrolizumab and atezolizumb presented lower toxicity profiles than second-line chemotherapy ([@B18], [@B19]).

###### 

Treatment characteristics of the eligible phase III randomized controlled trials for network meta-analysis.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Study**                                             **Treatment arm**   **Control arm**                                                                 **Dose of regimens (mg/m^**2**^)**   **No. of planned cycles**   **Median OS, months (treatment/control) (*p*-value)**   **HR for OS (95% CI)**   **Grade 3--4 Toxicity, % (treatment/control)**
  ----------------------------------------------------- ------------------- ------------------------------------------------------------------------------- ------------------------------------ --------------------------- ------------------------------------------------------- ------------------------ ------------------------------------------------
  Albers et al. ([@B12])                                Short-term GP       Prolonged GP                                                                    Gemcitabine: 1,000\                  6                           7.8/8.0 (0.772)                                         NA                       6.6/26.6
                                                                                                                                                            Paclitaxel: 175                                                                                                                                   

  Bellmunt et al. ([@B13]) (NCT00315237)                Vinflunine          BSC alone                                                                       320 or 280                           NA                          6.9/4.3 (0.040)                                         0.77 (0.61--0.98)        19.3/17.9

  Bellmunt et al. ([@B14])                              Vinflunine          BSC alone                                                                       320 or 280                           NA                          6.9/4.3 (0.023)                                         0.78 (0.61--0.96)        NA

  Harshman et al. ([@B15])                              Vinflunine          BSC alone                                                                       320 or 280                           NA                          6.9/4.7 (0.043)                                         0.76 (0.58--0.99)        NA

  Powles et al. ([@B16]) (NCT00949455)                  Lapatinib           Placebo                                                                         1,500 (fixed dose)                   NA                          12.6/12.0 (0.80)                                        0.96 (0.70--1.31)        8.6/8.1

  Bellmunt et al. ([@B18]) (NCT02256436, KEYNOTE-045)   Pembrolizumab       Investigator\'s choice of chemotherapy (paclitaxel, docetaxel, or vinflunine)   Pembrolizumab: 200 (fixed dose)\     NA                          10.4/7.4 (0.002)                                        0.73 (0.59--0.91)        15.0/49.4
                                                                                                                                                            Paclitaxel: 175\                                                                                                                                  
                                                                                                                                                            Docetaxel: 75\                                                                                                                                    
                                                                                                                                                            Vinflunine: 320                                                                                                                                   

  Powles et al. ([@B19]) (NCT02302807, IMvigor211)      Atezolizumab        Investigator\'s choice of chemotherapy (paclitaxel, docetaxel, or vinflunine)   Atezolizumab: 1,200 (fixed dose)\    NA                          11.1/10.6 (0.41)                                        0.87 (0.63--1.21)        20/43
                                                                                                                                                            Paclitaxel: 175\                                                                                                                                  
                                                                                                                                                            Docetaxel: 75\                                                                                                                                    
                                                                                                                                                            Vinflunine: 320                                                                                                                                   
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*BSC, best supportive care; GP, gemcitabine and paclitaxel; NA, non-available; OS, overall survival; HR, hazard ratio; CI, confidence interval*.

Bayesian Framework Network Meta-Analysis
----------------------------------------

Networks for indirect comparisons among multiple second-line treatments in terms of OS are described in [Figure 2](#F2){ref-type="fig"}. A fixed effects model was applied since the DIC of the fixed effects model was lower than that of the random effects model.

![Network geometry of clinical trials on second-line therapeutic agents for overall survival in metastatic urothelial carcinoma. Lines with arrows represent direct comparison between two treatments (set the side from which the arrow leaves as control arm). Gray line implies indirect comparison between two treatments.](fonc-09-00679-g0002){#F2}

Results of NMA are depicted in [Figure 3](#F3){ref-type="fig"}. When vinflunine was used as the reference for comparison, atezolizumab (HR, 0.90; 95% CrI, 0.57--1.40) and pembrolizumab (HR, 0.77, 95% CrI, 0.48--1.20) showed no significant efficacy in terms of OS benefit. Likewise, GP combination had no significant effect on OS (HR, 1.30; 95% CrI, 0.80--1.90) compared with atezolizumab. There was no significant difference in OS between lapatinib and control (best supportive care; BSC) either (HR, 0.95; 95% CrI, 0.57--1.60).

![Pooled hazard ratio and 95% credible intervals for network meta-analysis of the impact of each second-line therapeutic agent on overall survival.](fonc-09-00679-g0003){#F3}

[Figure 4](#F4){ref-type="fig"} presents SUCRA plots of six different second-line treatments (including control) in terms of OS benefit. Despite the lack of statistical significance in results of NMA, SUCRA analyses revealed that pembrolizumab and atezolizumab had high likelihood of being ranked first (\~65% probability) and second (about 40% probability), respectively. However, GP combination and lapatinib were most likely to be ranked the worst, inferior to the control.

![Rankograms for second-line treatment network of overall survival. The size of each bar corresponds to the probability of each treatment to be at a specific rank.](fonc-09-00679-g0004){#F4}

Publication Bias
----------------

There was no strong evidence of publication bias in that the funnel plot showed a certain degree of symmetry in the NMA of OS ([Supplementary Figure 1](#SM2){ref-type="supplementary-material"}). Also, the Begg\'s and Egger\'s tests demonstrated that there was no statistically significant publication bias in the NMA of OS (all *p*-values \> 0.05; [Supplementary Figure 1](#SM2){ref-type="supplementary-material"}).

Discussion {#s4}
==========

Although platinum (cisplatin or carboplatin)-based combination chemotherapy has been used as the primary treatment to improve survival outcomes in mUC patients, a substantial number of patients have experienced disease progression during or after the first-line platinum-based combination chemotherapy. Thus, secondary treatment is usually considered for such patients ([@B1], [@B2]). Several single chemotherapeutic agents have been investigated in second-line setting of mUC. However, no survival benefit, poor response rate, and significant treatment related-toxicity have been reported in association with second-line chemotherapy ([@B8], [@B9]). Currently, there are no US-FDA approved second-line chemotherapeutic agents for mUC.

Several therapeutic agents have been explored in phase III RCT design at second-line setting of mUC. Bellmunt et al. ([@B13], [@B14]) have reported that vinflunine with best supportive care (BSC) show a modest ORR of 8.6% and a meaningful survival gain of 2.6 months compared with BSC alone. Based on these results, vinflunine is currently the only second-line chemotherapeutic agent in mUC approved by European Medicines Agency in Europe. Short-term vs. prolonged second-line treatment using GP combination has been compared in a phase III RCT ([@B12]). Results showed that OS (7.8 vs. 8.0 months) was similar in both groups. However, treatment-related toxicity rate was relatively higher in the prolonged GP group (26.6%) than that in the short-term GP group (6.6%) ([@B12]). Irrespective of treatment duration, high response rate of up to 40% was observed in each group (37.5% in short-term GP vs. 41.5% in prolonged GP) ([@B12]). There have been studies on other agents as second-line treatment besides cytotoxic chemotherapy drugs. Lapatinib known as a TKI of HER pathway has been compared with placebo in second-line setting of mUC. Results of that study demonstrated that no significant differences in end-points of interest such as median progression-free survival (4.5 vs. 5.1 months), OS (12.6 vs. 12.0 months), or rate of grade 3--4 toxicities (8.6 vs. 8.1%) between the two groups ([@B16]). In recent years, systemic immunotherapy represented by immune checkpoint inhibition (ICI) has been vigorously assessed as a promising therapeutic option for various metastatic solid tumors, including mUC. Several comparative studies of ICI drugs and cytotoxic chemotherapy as second-line treatment in mUC through phase III RCT have been reported ([@B18], [@B19]). In KEYNOTE-045 trial, pembrolizumab (PD-1 inhibitor) showed superior response rate (21.1 vs. 11.4%), significant OS benefit (10.3 vs. 7.4 months), and better tolerable grade 3 or more toxicity profiles (15.0 vs. 49.4%) compared to chemotherapy ([@B18]). However, atezolizumab (PD-L1 inhibitor) did not show significant difference in terms of OS (11.1 vs. 10.6 months) or response rate (13.4% in each group) relative to chemotherapy in IMvigor 211 trial, although safety profiles (grade 3--4 toxicities) of atezolizumab were more favorable than chemotherapy (20 vs. 43%) ([@B19]). Notably, commonly observed feature in ICI related studies is that the response rate to treatment is not high (ranged from 10 to 20%). However, if response is observed, the response tends to be maintained during the treatment period ([@B17]).

However, there is no consensus on which of these drugs is the optimal second-line treatment for mUC. In the current study, we sought to evaluate the optimal second-line therapeutic agent in terms of OS improvement by indirectly comparing agents mentioned above. To the best of our knowledge, this is the first report pooling multiple second-line treatment agents of mUC (vinflunine, GP combination, lapatinib, atezolizumab, and pembrolizumab) assessed in previous phase III RCTs ([@B12]--[@B16], [@B18], [@B19]). NMA was applied for indirect comparison among these included drugs and SUCRA analysis was used to rank these included agents. Our NMA results showed no statistically significant OS differences among these assessed agents. However, SUCRA analysis demonstrates that it is highly likely that ICI drugs, including pembrolizumab and atezolizumab, are the preferred second-line therapeutics in mUC. A recently published study ([@B26]) using NMA has pooled previous three RCTs ([@B13], [@B18], [@B19]) and reported that all three drugs (vinflunine, pembrolizumab, and atezolizumab) showed a significant response rate compared with BSC. However, the rate of treatment discontinuation due to side effect was significantly higher in chemotherapy than that in BSC. In comparison with BSC, two ICI drugs demonstrated no significant treatment stop rate for adverse events while only pembrolizumab was associated with significant OS benefit ([@B28]). These analytic results suggest that ICI has durable therapeutic response and tolerable safety profiles. Thus, ICI drugs may be considered as the first option for second-line treatment of mUC ([@B11], [@B17]). Currently, there are several ongoing clinical trials which evaluate the combined treatment strategies with ICI and other therapeutic modalities, such as chemotherapy, target therapy, and other ICI (i.e., anti-CTLA-4 inhibitor), in the first or second-line and beyond setting of mUC ([Supplementary Table 1](#SM1){ref-type="supplementary-material"}). There have been also several clinical trials evaluating the inhibition of growth factor receptor (GFR) as a promising therapeutic target in mUC ([@B29], [@B30]) ([Supplementary Table 1](#SM1){ref-type="supplementary-material"}). Ramucirumab, which is a human IgG1 antibody to vascular-endothelial GFR-2 (VEGFR-2), and docetaxel combination presented favorable progression-free survival than chemotherapy plus placebo in patients with platinum-refractory mUC as a result of phase III RCT ([@B29]). Recently, erdafitinib, a pan-fibroblast GFR (FGFR) inhibitor, was granted accelerated US-FDA approval for the use in patients with locally advanced or metastatic UC with susceptible FGFR3 or FGFR2 genetic alterations who have progressed during or after platinum-containing chemotherapy based on the results of a phase II clinical trial ([@B30]). When the results of these ongoing clinical trials are published, it is expected to provide evidence for novel treatment strategies for mUC, further changing the treatment paradigm.

The present study has some limitations. First, although our study only included previously reported phase III RCTs for NMA, the association between second-line treatments and OS could not be controlled through multivariate analysis with other variables such as treatment-induced toxicity and patient dropout which might have affected results of this study. Besides, there might be differences in patient background among anticancer agents. Although these differences could not be easily identified and adjusted, they might have effect on the results of the study if considered when agents are compared. Second, the primary end-point of this analysis only included OS improvement. Therefore, we did not assess the relationship between second-line therapeutic agents and other clinical outcomes, including treatment-related side effects and response rates. Even if the final goal of cancer treatment is to improve the survival of patients, adverse events, and response rates for treatment might have significant impact on the choice of treatment modality. If these factors were considered as other end-points in the analysis, it might be possible to provide a more crucial basis for finding the optimal second-line therapeutic agent in mUC. Lastly, the current study only included full-text articles published in English which might lead to language bias ([@B31]), although there was no evidence of publication bias in the present study.

Conclusions {#s5}
===========

Results of our study were inconclusive in view of the inability to determine the optimal second-line treatment for OS improvement because there were no significant OS differences among evaluated therapeutic agents based on results of NMA. However, the use of ICI drugs such as atezolizumab and pembolizumab may be given priority for improving OS in second-line setting of mUC.
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